Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts
Abstract
Serdemetan (JNJ-26854165) is a novel tryptamine compound with antiproliferative activity in various p53 wild-type (WT) tumor cell lines. We investigated its potential as radiosensitizer using four human cancer cell lines: H460, A549, p53-WT-HCT116, and p53-null-HCT116. Serdemetan inhibited clonogenic survival in all cell lines, but in a lower extent in p53-null-HCT116. In the combination studies, Serdemetan treatment at 0.25μM in H460 and at 5μM in A549 cells resulted in a sensitivity-enhancement ratio of 1.18 and 1.36, respectively. At 2Gy, surviving fractions were 0.72 and 0.97 for p53-WT HCT116 and p53-null cells exposed to 0.5μM of Serdemetan, respectively (p<0.05). Radiosensitization of H460 and A549 cells was associated with G2/M cell cycle arrest and with an increased expression of p53 and p21. In vivo, Serdemetan caused a greater than additive increase in tumor growth delay. The dose enhancement factor was 1.9 and 1.6 for H460 and A549 tumors, respectively. Serdemetan inhibited proliferation, capillary tube formation and migration of HMEC-1 cells. These effects were more marked concurrently with irradiation. These results in tumor and endothelial cells suggest that Serdemetan has potential as a radiosensitizer. Further investigations are warranted with regard to the molecular mechanisms underlying its actions and its dependency regarding p53 status.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
More preclinical studies reported that JNJ-26854165 increased p53 levels in U87 glioblastoma grafts, accompanied by apoptotic stimulation.
“More preclinical studies reported that JNJ-26854165 increased p53 levels in U87 glioblastoma grafts, accompanied by apoptotic stimulation.373–376”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [373]
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · see citing works
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · see citing works
Role of cell cycle in mediating sensitivity to radiotherapy
Pawlik, T. M., & Keyomarsi, K. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.03.005 · Cited by 1,101 · see citing works
Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660 · see citing works
Modeling the Therapeutic Efficacy of p53 Restoration in Tumors
Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600 · see citing works
Enge, M., Bao, W., Hedström, E., Jackson, S. P., Moumen, A., & Selivanova, G. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.019 · Cited by 171 · see citing works
Targeting p53 for enhanced radio- and chemo-sensitivity
Lü, C., & El‐Deiry, W. S. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0330-1 · Cited by 134 · see citing works
Antiangiogenic Activity of the MDM2 Antagonist Nutlin-3
Secchiero, P., Corallini, F., Gonelli, A., Dell’Eva, R., Vitale, M., Capitani, S., Albini, A., & Zauli, G. (2006) · Circulation Research · doi:10.1161/01.res.0000253975.76198.ff · Cited by 125 · see citing works
Miyachi, M., Kakazu, N., Yagyu, S., Katsumi, Y., Tsubai-Shimizu, S., Kikuchi, K., Tsuchiya, K., Iehara, T., & Hosoi, H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2955 · Cited by 101 · see citing works
Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer
Patel, S., & Player, M. R. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802493366 · Cited by 99 · see citing works
Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2
Cao, C., Shinohara, E. T., Subhawong, T. K., Geng, L., Kim, K. W., Albert, J. M., Hallahan, D. E., & Lü, B. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0356 · Cited by 85 · see citing works
Kojima, K., Burks, J. K., Arts, J., & Andreeff, M. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0337 · Cited by 78 · see citing works
Self-citationRaju, U., Nakata, E., Mason, K. A., Ang, K. K., & Milas, L. (2003) · PubMed · Cited by 74 · see citing works
Arya, A. K., El-Fert, A., Devling, T., Eccles, R. M., Aslam, M. A., Rubbi, C. P., Vlatković, N., Fenwick, J. D., Lloyd, B. H., Sibson, D. R., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605739 · Cited by 72 · see citing works
New Molecular Targeted Therapies Integrated With Radiation Therapy in Lung Cancer
Provencio, M., Sánchez, A., Garrido, P., & Valcárcel, F. (2010) · Clinical Lung Cancer · doi:10.3816/clc.2010.n.012 · Cited by 64 · see citing works
A p53 and apoptotic independent role for p21waf1 in tumour response to radiation therapy
Wouters, B. G., Denko, N. C., Giaccia, A. J., & Brown, J. M. (1999) · Oncogene · doi:10.1038/sj.onc.1203053 · Cited by 50 · see citing works
Nutlins and Ionizing Radiation in Cancer Therapy
Impicciatore, G. G., Sancilio, S., Miscia, S., & Pietro, R. D. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791033932 · Cited by 49 · see citing works
PTEN/pAkt/p53 signaling pathway correlates with the radioresponse of non-small cell lung cancer
Kim, N. K. (2010) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000372 · Cited by 49 · see citing works
Kurosu, T., Wu, N., Oshikawa, G., Kagechika, H., & Miura, O. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0457-0 · Cited by 43 · see citing works
Sun, S. H., Zheng, M., Ding, K., Wang, S., & Sun, Y. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.6.5841 · Cited by 36 · see citing works
Grünbaum, U., Meye, A., Bache, M., Bartel, F., Würl, P., Schmidt, H., Dunst, J., & Taubert, H. W. (2001) · PubMed · Cited by 20 · see citing works
Maggiorella, L., Aubel, C., Haton, C., Milliat, F., Connault, E., Opolon, P., Deutsch, É., & Bourhis, J. (2008) · Cell Proliferation · doi:10.1111/j.1365-2184.2008.00570.x · Cited by 15 · see citing works
Self-citationStühmer, T., Arts, J., King, P., Page, M., Bommert, K., Leo, E., & Bargou, R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.14694 · Cited by 7 · see citing works
Self-citationHuntjens, D. R. H., van Beijsterveldt, L., & Kraljevic, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.e13011 · Cited by 2 · see citing works
Jones, R. J., Arts, J. J. G., & Orlowski, R. Z. (2008) · Blood · doi:10.1182/blood.v112.11.3618.3618 · Cited by 2 · see citing works
Self-citation
Flagged first, then by citations
1 of the 26 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
The role of ubiquitination in tumorigenesis and targeted drug discovery
Deng, L., Meng, T., Chen, L., Wei, W., & Wang, P. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0107-0 · Cited by 744 · see citing works
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works
Deep learning-guided discovery of an antibiotic targeting Acinetobacter baumannii
Liu, G., Catacutan, D. B., Rathod, K., Swanson, K., Jin, W., Mohammed, J. C., Chiappino-Pepe, A., Syed, S. A., Fragis, M., Rachwalski, K., et al. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01349-8 · Cited by 366 · see citing works
“1d,e); serdemetan 22,23 is an antagonist of the transcription factor HDM2 that displayed MIC of ~32 µg ml −1 (Extended Data Fig.”
BackgroundUbiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches
Liu, F., Chen, J., Li, K., Li, H., Zhu, Y., Zhai, Y., Lu, B., Fan, Y., Liu, Z., Chen, X., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02046-3 · Cited by 352 · see citing works
The Roles of MDM2 and MDMX in Cancer
Karni-Schmidt, O., Lokshin, M., & Prives, C. L. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040349 · Cited by 294 · see citing works
Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils
Stegh, A. H. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.643299 · Cited by 192 · see citing works
“Candidates include reactivation of p53 and induction of tumor cell apoptosis (RITA), which showed antitumor effects in murine colon cancer models by inducing conformational changes in p53 thereby preventing interaction with Mdm proteins [184], and the tryptamine derivate JNJ-26854165, which blocked p53 proteasomal deg…”
BackgroundTargeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
Nag, S. A., Zhang, X., Srivenugopal, K. S., Wang, M.-H., Wang, W., & Zhang, R. (2014) · Current Medicinal Chemistry · doi:10.2174/09298673113206660325 · Cited by 151 · see citing works
The roles and regulation of MDM2 and MDMX: it is not just about p53Preprint
Klein, A. M., de Queiroz, R. M., Venkatesh, D., & Prives, C. L. (2021) · Genes & Development · doi:10.1101/gad.347872.120 · Cited by 132 · see citing works
“Taken together with the study where serdemetan elicited an anticancerous response in multiple patient-derived xenografts harboring either mutant or wild-type p53 (Chargari et al. 2011), there is a need for additional research into its clinical effectiveness.”
BackgroundEmerging therapies targeting the ubiquitin proteasome system in cancer
Weathington, N. M., & Mallampalli, R. K. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71602 · Cited by 124 · see citing works
Targeting Ubiquitination for Cancer Therapies
Morrow, J. K., Lin, H., Sun, S., & Zhang, S. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.148 · Cited by 101 · see citing works
Yang, D., Tan, M., Wang, G., & Sun, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034079 · Cited by 93 · see citing works
“In fact, radiosensitiation of H460 and A549 lung cancer cells by a tryptamine compound, and of PC-3 prostate cancer cells by genistein also involved p21 induction and G2/M arrest [57,58].”
BackgroundNovel strategies to target the ubiquitin proteasome system in multiple myeloma
Lub, S., Maes, K., Menu, E., Bruyne, E. D., Vanderkerken, K., & Valckenborgh, E. V. (2015) · Oncotarget · doi:10.18632/oncotarget.6658 · Cited by 83 · see citing works
“Serdemetan, another HDM2-p53 inhibitor, specifically binds to the ring domain of HDM2, thereby inhibiting the binding of the HDM2-p53 complex to the proteasome and preventing the degradation of p53 [109].”
BackgroundTargeting p53-MDM2-MDMX Loop for Cancer Therapy
Zhang, Q., Zeng, S. X., & Lu, H. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_16 · Cited by 83 · see citing works
“For example, a small molecule named JNJ-26854165 was shown to bind the RING domain of MDM2 and prevent the interaction of the MDM2-p53 complex with the proteasome and has been put on phase I clinical trial for advanced or refractory tumor [45, 46].”
BackgroundReviving the guardian of the genome: Small molecule activators of p53
Nguyen, D., Liao, W., Zeng, S. X., & Lu, H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.013 · Cited by 80 · see citing works
“…theMDM2-p53 complex from interacting with the proteasome and has progressed to phase I clinical trials for advanced stage or refractory tumors (Chargari et al., 2011; Kojima, Burks, Arts, & Andreeff, 2010; Patel & Player, 2008; Tabernero et al., 2011) (NCT00676910),while HLI98s and related…”
BackgroundBi, Y., Qiu, C., Yang, M., Xing, L., & Jiang, H. (2024) · Nature Communications · doi:10.1038/s41467-024-47080-3 · Cited by 67 · see citing works
“44, 45).”
MethodNutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
VOON, Y.-L., Wong, P., & Khoo, A. S. B. (2017) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557517666170717125821 · Cited by 65 · see citing works
Small molecule compounds targeting the p53 pathway: are we finally making progress?
Yu, X., Narayanan, S., Vázquez, A., & Carpizo, D. R. (2014) · APOPTOSIS · doi:10.1007/s10495-014-0990-3 · Cited by 65 · see citing works
“JNJ-26854165 (Serdemetan) Inhibits p53-MDM2 binding MDM2 Phase I clinical trial (NCT00676910) [58, 60]”
BackgroundWang, J., Wang, Y., Mei, H., Yin, Z., Geng, Y., Zhang, T., Wu, G., & Lin, Z. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.031 · Cited by 52 · see citing works
Kurmi, B. D., Patel, P., Paliwal, R., & Paliwal, S. R. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101682 · Cited by 49 · see citing works
MDM2/X inhibitors as radiosensitizers for glioblastoma targeted therapy
Miles, X., Vandevoorde, C., Hunter, A., & Bolcaen, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703442 · Cited by 40 · see citing works
Li, Z., Li, J., Yang, N., Chen, Y., Zhou, Y., Ji, X., Zhang, L. J., Wang, J., Xie, X., & Liu, H. S. (2013) · The Journal of Organic Chemistry · doi:10.1021/jo4017887 · Cited by 40 · see citing works
Targeting the neddylation pathway in cells as a potential therapeutic approach for diseases
Ying, J., Zhang, M., Qiu, X., & Yu, L. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3541-8 · Cited by 39 · see citing works
Inhibitors of ubiquitin E3 ligase as potential new antimalarial drug leads
Jain, J., Jain, S. K., Walker, L., & Tekwani, B. L. (2017) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-017-0147-4 · Cited by 27 · see citing works
“JNJ 26854165, also known as Serdemetan, is a tryptamine derivative and interrupts the HDM2-p53 binding and is in phase 1 clinical trial for the treatment of multiple myelomas [21, 22, 24].”
Recent Synthetic Approaches towards Small Molecule Reactivators of p53
Silva, J. L., Lima, C. G. S., Rangel, L. P., Ferretti, G. D. S., Pauli, F. P., Ribeiro, R. C. B., Silva, T. B., da Silva, F. D. C., & Ferreira, V. F. (2020) · Biomolecules · doi:10.3390/biom10040635 · Cited by 28 · see citing works
“In 2011, Deutsch and co-wo kers reported the action of JNJ-26854165 against several types of human cancer cell lines; although a mechanism of action was not proposed, the authors verified that this compound also has potential as a photosensitizer [145].”
BackgroundJones, R. J., Gu, D., Bjorklund, C. C., Kuiatse, I., Remaley, A. T., Bashir, T., Vreys, V., & Orlowski, R. Z. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.204958 · Cited by 26 · see citing works
“, 2008) and have activity in cancer cell lines (Kojima et al., 2010; Chargari et al., 2011).”
BackgroundInfluentialSelf-citationThe emerging roles of E3 ubiquitin ligases in ovarian cancer chemoresistance
Meng, Y., Qiu, L., Zhang, S., & Han, J. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2020.115 · Cited by 17 · see citing works
“Many compounds, including nutlin-3 (RO5045337), serdemetan, and NSC-207895, have all demonstrated in vitro anticancer activities([137-139]).”
BackgroundNagaraju, V., Purnachander, D., Goutham, K., Suresh, S., Sridhar, B., & Karunakar, G. V. (2016) · Asian Journal of Organic Chemistry · doi:10.1002/ajoc.201600349 · Cited by 16 · see citing works
Progress in Anticancer Drug Development Targeting Ubiquitination-Related Factors
Li, Q., & Zhang, W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315104 · Cited by 16 · see citing works
Molecular Pathways: Turning Proteasomal Protein Degradation into a Unique Treatment Approach
Stintzing, S., & Lenz, H. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3175 · Cited by 16 · see citing works
Ye, Q., Raese, R. A., Luo, D., Feng, J., Xin, W., Dong, C., Qian, Y. R., & Guo, N. L. (2023) · Cells · doi:10.3390/cells12141917 · Cited by 15 · see citing works
“In a Phase I clinical study, Serdemetan was well tolerated by patients with advanced solid tumors with exposure-related QTc liability, and partial response was observed in a breast cancer patient [88].”
BackgroundSerdemetan Antagonizes the Mdm2-HIF1α Axis Leading to Decreased Levels of Glycolytic Enzymes
Lehman, J. A., Hauck, P. M., Gendron, J. M., Batuello, C. N., Eitel, J. A., Albig, A. R., Kadakia, M., & Mayo, L. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074741 · Cited by 14 · see citing works
“Serdemetan does not appear to alter endothelial cells as measured by in vitro neo-vessel formation in matrigel [7].”
BackgroundPossenti, L., Mecchi, L., Rossoni, A., Sangalli, V., Bersini, S., Cicchetti, A., Costantino, M. L., Candrian, C., Arrigoni, C., Rancati, T., et al. (2021) · Cancers · doi:10.3390/cancers13051182 · Cited by 13 · see citing works
Prajapati, A., Kachhadiya, R. N., Pravin, M. A., Singh, S. K., Patel, H. D., & Patel, S. (2025) · ChemistrySelect · doi:10.1002/slct.202501564 · Cited by 10 · see citing works
Identification of anticancer drugs to radiosensitise BRAF-wild-type and mutant colorectal cancer
Carter, R., Cheraghchi-Bashi, A., Westhorpe, A., Sheng, Y., Shanneik, Y., Elena, S., Ouaret, D., Yasuhiro, I., Catherine, K., Wilding, J., et al. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0284 · Cited by 9 · see citing works
Development of MDM2‐Targeting PROTAC for Advancing Bone Regeneration
Jeong, S., Cha, J., Ahmed, W., Kim, J., Kim, M., Hong, K. T., Choi, W., Choi, S., Yoo, T. H., An, H., et al. (2025) · Advanced Science · doi:10.1002/advs.202415626 · Cited by 9 · see citing works
Dual functionality of MDM2 in PROTACs expands the horizons of targeted protein degradation
Zhao, J., Chen, H., & Liang, C. (2025) · Biomarker Research · doi:10.1186/s40364-025-00826-7 · Cited by 7 · see citing works
“Serdem-etan (JNJ-26854165), an E3 ligase activity inhibitor, prevents MDM2-proteasome binding but has limited clinical use due to toxicity and off-target effects [145].”
MDM2/P53 Inhibitors as Sensitizing Agents for Cancer Chemotherapy
Zhu, Y. Y., Wang, H., & Thuraisamy, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816435-8.00015-8 · Cited by 7 · see citing works
Xu, Z., Lei, Z., Peng, S., Li, S., Kong, D., Duan, H., Zhang, M., Su, G., & Pan, G. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1541489 · Cited by 4 · see citing works
CT‑1042, a novel anticancer agent, exhibits effects by activating p53 and inhibiting survivin
Yang, J., Li, L., Xu, C., Yang, D., Wang, S., & Yuan, S. (2018) · Oncology Reports · doi:10.3892/or.2018.6354 · Cited by 4 · see citing works
Jeong, S., An, S.-C., An, H., Lim, S. Y., Kim, J. M., & Lee, S. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118686 · Cited by 4 · see citing works
Activation of wild-type p53 by MDM2 inhibitors: a new strategy for lymphoma treatment
Pujals, A., Favre, L., Gaulard, P., & Wiels, J. (2015) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s60486 · Cited by 3 · see citing works
Qi, X., Zuo, J., Yan, D., Hu, G., Wang, R., Chen, J., & Fu, J. (2021) · Current Bioinformatics · doi:10.2174/1574893616666211005122422 · Cited by 3 · see citing works
Chang, H. R. (2023) · Biomedicines · doi:10.3390/biomedicines11092527 · Cited by 2 · see citing works
Park, I. A., Noh, Y., Min, K., Kim, D., Lee, J., Son, B. K., Kwon, M. J., Han, M., Hur, J. Y., & Pyo, J. (2024) · Journal of Breast Cancer · doi:10.4048/jbc.2024.0107 · Cited by 1 · see citing works
“Serdemetan inhibits MDM2-p53 interaction, thereby activating p53 [55-57].”
Lam, B., Gulri, M. K., Akhtar, S., Lemieux, P., Tawadrous, M., Murugathasan, M., Sater, A. A. A., & Roudier, E. A. (2025) · The Journal of Physiology · doi:10.1113/jp288947 · Cited by 1 · see citing works
“ Some control samples for EZH2 and the hypo-phosphorylation antibody show low protein levels while others are comparable to trained.”
Marostica, E., Ammel, K. V., Teisman, A. C. H., Gallacher, D. J., Bocxlaer, J. V., Ridder, F. D., Boussery, K., & Vermeulen, A. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9920-3 · Cited by 1 · see citing works
Aguida, B., Bouceba, T., Créchet, J., Hounguè, H., Capo‐chichi, C. D., Nakayama, J., Baouz, S., Pelczar, H., Woisard, A., Jourdan, N., et al. (2019) · The Open Biochemistry Journal · doi:10.2174/1874091x01913010064 · Cited by 1 · see citing works
Nordor, A. V., Aryee, M. J., & Siwo, G. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/399311 · Cited by 1 · see citing works
Xu, N., Tong, Y., Ma, K., Jiang, L., & Zheng, W. (2025) · Medical Oncology · doi:10.1007/s12032-025-02912-0 · Cited by 1 · see citing works
“Serdemetan elevates p53 levels and inhibits migration, capillary formation, and cell proliferation in HMEC-1 cells [82, 83].”
Hamese, S., Takundwa, M. M., Prinsloo, E., & Raj, D. B. T. G. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.21.719801
Zamora, M. E., Muchow, M. R., Ray, I., McKinley-Pace, N. D., Kaplan, E. D., Branson, D. W., Santamaria, U. A., & Zamora, P. O. (2026) · Research Square · doi:10.21203/rs.3.rs-9559070/v1
Gu, H., Wang, S., Li, M., Guo, Y., Li, X., Gao, Z., Li, J., Liu, H., Zhou, X., & Xu, Y. (2026) · Pharmaceutical Science Advances · doi:10.1016/j.pscia.2026.100124
“It functions as a P53-MdM2 inhibitor and has demonstrated significant anti-proliferative activity against glioblastoma cells [31,32].”
Wu, Y., Yu, X., Guan, C., & Zhao, M. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1809222
- Authors
- Chargari, C., Leteur, C., Angevin, E., Bashir, T., Schoentjes, B., Arts, J., Janicot, M., Bourhis, J., & Deutsch, E.
- Affiliations
- Inserm (FR)
- Institut Gustave Roussy (FR)
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2011-12
- Volume
- 312
- Issue
- 2
- Pages
- 209-218
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W1993148588
- Cited by
- 54
- References
- 26
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 3 · 2023: 4 · 2022: 1 · 2021: 5 · 2020: 3 · 2019: 3 · 2018: 3 · 2017: 4 · 2016: 4 · 2015: 3 · 2014: 5 · 2013: 3 · 2012: 2
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Letters (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Radiation Therapy and Dosimetry
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Effects of Radiation Exposure
- Keywords
- tryptamine, radiosensitizers, p53, p21, G2/M cell cycle arrest, lung cancer cell lines, H460 cells, A549 cells, HCT116 cells, tumor xenografts, tumor growth inhibition, endothelial cell migration, angiogenesis, clonogenic survival
- MeSH terms
- Cell Cycle, Drug Evaluation, Preclinical, Humans, Radiation-Sensitizing Agents, Tryptamines, Blotting, Western, Tumor Suppressor Protein p53, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cyclin-Dependent Kinase Inhibitor p21, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
